Plasma tau biomarkers, particularly plasma p-tau217, have consistently shown excellent diagnostic performance across the AD continuum, recently culminating in regulatory approval of plasma p-tau217-based assays in both the USA and Europe.
Abstract
The introduction of blood-based biomarkers (BBMs) for Alzheimer’s disease (AD) represents one of the most transformative advances in neurodegenerative disease research over the past decade. 1,2 For the first time, biological evidence of AD pathology can be obtained through a minimally invasive, scalable blood test, opening new opportunities for early diagnosis, patient triage, and implementation of disease-modifying therapies. 3 Among the available biomarkers, phosphorylated tau (p-tau) species, particularly plasma p-tau217, have consistently shown excellent diagnostic performance across the AD continuum, recently culminating in regulatory approval of plasma p-tau217-based assays in both the USA and Europe. 4–6 Despite this remarkable clinical success, a fundamental paradox remains. Plasma tau biomarkers work
Routine and accessible plasma measures can be leveraged to recover reproducible, biologically distinct progression modules that improve characterization of heterogeneous AD and have practical value for risk stratification, trial enrichment, or treatment monitoring.
R. R. Butler, M. Brown, A. Weber et al.· medRxiv· 1 citation
A review of recent advances in BBMs through the ATN-I framework explores how integrating BBMs with traditional cerebrospinal fluid and neuroimaging tests may support symptom-driven clinical triage, probability refinement, and early evaluation in selected individuals, improving clinical workflow efficiency and accessibi...
B. Xie, Wang Zhang, Yu Zhang et al.· Frontiers in Aging Neuroscie...· 0 citations
Plasma biomarkers offer a transformative, non-invasive approach to early AD diagnosis and primary care triage, reducing reliance on CSF and PET scans and overcoming demographic and methodological limitations is essential for their widespread clinical adoption.
Małgorzata Witaszczyk, Alicja Sołtan, Natalia Wiktorzak et al.· International Journal of Inn...· 0 citations
The emergence of blood-based biomarkers (BBMs) has transformed the diagnosis of Alzheimer’s disease (AD). 1,2 Plasma phosphorylated tau, glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) have demonstrated remarkable accuracy in detecting amyloid pathology and predicting disease progression acr...
H. Kwon, Seong-Ho Koh· Journal of Clinical Neurolog...· 0 citations
Rare and common variants in AD- and neurodegenerative biomarker-associated genes with increased frequency in India compared to other populations may impact blood levels of neurodegenerative biomarkers in South Asians.
Hasan Abu-Amara, Wei Zhao, Zheng Li et al.· Frontiers in Aging Neuroscie...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
